Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod

The U.S. Food and Drug Administration approved ​Ultragenyx Pharmaceutical's gene therapy to ‌treat a rare metabolic disorder, the company said on Wednesday.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。